These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16129573)

  • 1. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
    Plandé J; Platel D; Tariosse L; Robert J
    Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity.
    Pearlman M; Jendiroba D; Pagliaro L; Keyhani A; Liu B; Freireich EJ; Travis E
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):477-81. PubMed ID: 12827292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
    Langer SW; Thougaard AV; Sehested M; Jensen PB
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):125-8. PubMed ID: 16001176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
    Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
    Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiac prevention: the oncologic point of view].
    Gligorov J; Debourdeau P; Arsovski O; Lotz JP
    Bull Cancer; 2004 Nov; 91 Suppl 3():192-200. PubMed ID: 15899627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.